Condition: Biliary Tract Cancer · Sponsor: Shanghai Zhongshan Hospital
The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.
This description comes directly from the study's public registry record.
Guoming Shi, M.D · 13916969578 · shi.guoming@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Shanghai Zhongshan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06620848